33results about How to "Play an antiviral role" patented technology

The present invention relates to an andrographolide sodium sulfonate freeze-dried powder injection preparation. Said freeze-dried powder injection preparation contains unit dose 10-1500 mg of andrographolide sodium sulfonate, and at least contains one pharmaceutically-acceptable carrier, said carrier includes excipient, pH regulating agent, anti-oxidant and stabilizing agent. Said invented powder injection preparation can be mainly used for curing the diseases of bronchitis, cystauchenitis, urethritis, pelvic inflammation, acute icterohepatitis anjd prostatitis, etc. Besides, said invention also provides its preparation process.

The invention relates to an application of lariciresinol-4-O-beta-D-glucoside in the preparation of drugs for treating or preventing flu and related inflammatory diseases caused by influenza virus. The application of lariciresinol-4-O-beta-D-glucoside in clinical treatment of influenza virus diseases has characteristics of safety, effectivity and little toxic or side effect. The invention also provides a pharmaceutical composition, an active ingredient of which comprises lariciresinol-4-O-beta-D-glucoside. By cytopathic-effect inhibition assay, it is verified that lariciresinol-4-O-beta-D-glucoside has an effect of inhibiting replication of influenza virus in the treatment mode. The result proves that lariciresinol-4-O-beta-D-glucoside has obvious effect of inhibiting influenza virus in the treatment mode. Selection index SI is greater than 4. The lariciresinol-4-O-beta-D-glucoside has advantages of low toxicity and high effectiveness.

The invention provides an antiviral traditional Chinese medicinal slow-release granule for aquaculture and a preparation method of the traditional Chinese medicinal slow-release granule. The antiviraltraditional Chinese medicinal slow-release granule is formed by reasonable matching and has the efficacy of clearing heat and detoxicating, resisting bacteria and eliminating inflammation and the like. The test proves that the traditional Chinese medicinal slow-release granule disclosed by the invention has the functions of resisting viruses, inhibiting germs and the like, and has the advantagesof high safety, no residues in aquatic animal bodies and no drug resistance; in addition, the formula is reasonable and simple and the cost is low; the antiviral traditional Chinese medicinal slow-release granule is especially suitable for culturing grass carp, crucian carp and carp; by coating the surface of a core material with a wall material, the drug properties are slowly released, and the dosage is reduced, so that lower economic cost and smaller influence on a water body are realized. By carrying different traditional Chinese medicinal materials of the core material, different slow-release granules for different fishes can be developed in a targeted manner, and have high pertinence and small influence on other fishes. By arranging gypsum and lard oil, the slow-release granule can bekept in agglomeration in water and suspend in the water body; the drug is slowly released and further favorably attracts the fishes to eat. The folium isatidis and herba houttuyniae can resist viruson the one hand and can achieve the effect of feeding attraction on the other hand.

The present invention discloses a small molecular double stranded RNA group prepared from yeast, a preparation method and a use thereof. According to the present invention, the small molecular double stranded RNA group is prepared through adopting a mixture and the total RNA of the yeast as substrates, wherein the mixture comprises at least two selected from ribonuclease T1, deoxyribonuclease I and ribonuclease III, the yeast is the yeast which kills plasmids. The small molecular double stranded RNA group provided by the present invention can be provided for preparing cancer prevention care products, anti-cancer health care products and anti-virus health care products. The preparation method provided by the present invention is simple, and is easy to operate.

The invention relates to an application of lariciresinol-4-O-beta-D-glucoside in the preparation of drugs for treating or preventing flu and related inflammatory diseases caused by influenza virus. The application of lariciresinol-4-O-beta-D-glucoside in clinical treatment of influenza virus diseases has characteristics of safety, effectivity and little toxic or side effect. The invention also provides a pharmaceutical composition, an active ingredient of which comprises lariciresinol-4-O-beta-D-glucoside. By cytopathic-effect inhibition assay, it is verified that lariciresinol-4-O-beta-D-glucoside has an effect of inhibiting replication of influenza virus in the treatment mode. The result proves that lariciresinol-4-O-beta-D-glucoside has obvious effect of inhibiting influenza virus in the treatment mode. Selection index SI is greater than 4. The lariciresinol-4-O-beta-D-glucoside has advantages of low toxicity and high effectiveness.

The invention provides an infectious bovine rhinotracheitis virus (IBRV) aptamer. The aptamer has the maximum binding force and favorable specificity, can inhibit the virus infection on cells to some extent, and can be used for indirect immunofluorescent assay (IFA) after being marked by FAM. The aptamer can be used for inhibiting the virus infection on cells to perform the antivirus action, and can also be used as an anti-IBRV probe or target spot for preparing anti-IBRV drugs or reagents.

The invention discloses a H3N2 canine influenza virus shuttle intracellular antibody. The H3N2 virus is a type A influenza virus, and the main neutralizing antibody comes from the surface glycoprotein hemagglutinin (HA), so HA has become the main research target in the past; However, influenza virus is highly variable, and the immune cross-reaction between different variant branches is weak. M1 antibody can bind to M1 protein, inhibit its activity, interfere with the replication, transcription and release of influenza virus, and thus play an antiviral role. Therefore, we choose M1 protein to prepare the corresponding antibody to obtain a stable titer, couple it with TAT protein PTD, which can transduce biological macromolecules into cells, express the fusion protein TAT PTD‑M1 ScFv, and prepare anti- The shuttle antibody of canine influenza virus provides a new way for the treatment of canine influenza.

The invention discloses a H3N2 canine influenza virus shuttle intracellular antibody TAT‑4F. The H3N2 virus is a type A influenza virus, and the most important neutralizing antibody comes from the surface glycoprotein hemagglutinin (HA), so HA has become the main antibody in the past. Research targets; however, influenza viruses are highly variable, and the immune cross-reaction between different variant branches is weak. M1 antibodies can bind to M1 protein, inhibit its activity, and interfere with the replication, transcription and release of influenza viruses, thus playing a role To this end, we choose the M1 protein to prepare the corresponding antibody to obtain a stable titer, couple it with the TAT protein PTD, which can transduce biological macromolecules into cells, and express the fusion protein TAT PTD‑M1 ScFv, The shuttle antibody against canine influenza virus was prepared, which provided a new way for the treatment of canine influenza.

The invention discloses an anti-H5N1 virus cell-entry antibody PTD‑3F, the base sequence of which is shown in the sequence table SEQ ID NO.5; a fusion protein PTD‑3F , its amino acid sequence is shown in the sequence table SEQ ID NO.6; fusion protein PTD‑3F Preparation method 1) Use primers to amplify the 3F gene using the screened phage antibody ScFv gene as a template; 2) Link the amplified 3F gene to PET28a‑ PTD‑GFP In the vector, the prokaryotic expression vector PET28a‑ PTD ‑3F; 3) Prokaryotic expression vector transformed into Escherichia coli for expression and purification; a fusion protein PTD‑3F Application in the preparation of anti-H5N1 type human avian influenza virus medicine; the results show that the intracellular antibody can neutralize the activity of H5N1 virus, and the titer is 400TCID50.

The invention provides a display device and a manufacturing method thereof. The display device is provided with a display device body and a coating located on the surface of the display device, and the coating contains nanometer calcium tungstate. The coating containing nanometer calcium tungstate is arranged on the surface of the display device body so as to play an antiviral role, have a virus inhibiting function, be beneficial to providing the healthy life for human beings and further improve the quality of life. The virus includes but not limited to murine herpetoviruses(MHV-68), murine coronaviruses (MHV-A59), avian influenza viruses (H9N2) and the like.

The invention provides Heinz sargassum fucoidan sulfate, which is composed of fucose and galactose and has a molecular weight of 4.0×10 5 -6.0×10 5 , Sargassum Heinzii Fucoidan Sulfate is extracted from Sargassum Heinzli; by extracting the crude polysaccharide from Sargassum Heinzii, and then purifying the crude polysaccharide through ion exchange chromatography and molecular sieve column for many times, it can be used for anti-herpes virus research Heinz Sargassum Fucosan Sulfate. This protocol can isolate natural polysaccharides with a novel antiviral mode of action, low toxicity and high efficiency, and safety and easy acceptance from marine medicinal resources Sargassum henzii. Research basis: Heinz Sargassum fucoidan sulfate can play an antiviral role by effectively inhibiting the adsorption of herpes virus to the surface of host cells. Its site of action is the cell surface and can act on the first step of virus infection. Entering cells, the possibility of causing toxic side effects is relatively small.

The invention discloses environmentally-friendly meat duck feed, which comprises the following raw materials in parts by weight: 40-60 parts of corns, 20-30 parts of soybean meal, 3-4 parts of rapeseed dregs, 0-11 parts of rice bran meal, 1-2 parts of mountain flour, 1-3 parts of dried folium mori, 2-5 parts of herba artemisiae annuae, 0-3 parts of dried cacumen platycladi, 0.5-2 parts of dried fructus crataegi, 1-3 parts of folium syringae, 1-2 parts of calcium hydrophosphate, 0.1-0.2 part of DL-methionine, 0-0.2 part of lysine, 0.3 part of vitamin and trace element premix and 0.5 part of composite additive premix. The corn, the soybean meal and the rapeseed dregs provide sufficient nutrition for ducks, the mountain flour and the calcium hydrophosphate perform a function of calcium supplementation, the dried folium mori, the herba artemisiae annuae and the dried cacumen platycladi perform a function of resisting bacteria, the dried fructus crataegi performs a function of inhibiting escherichia coli, pseudomonas aeruginosa and staphylococcus aureus, and the folium syringae performs a function of nourishing the stomach and increasing a digestion function. The environmentally-friendly meat duck feed can improve the immunity of ducks and reduce the utilization of antibiotics.